Search results
In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
These frequently asked questions should provide a response for most of the queries you might raise.
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.
Jenny Dewing is a postdoctoral researcher working on a Retina UK-funded project with Dr Arjuna Ratnayaka at the University of Southampton.
Simon spent 40 years as a consultant ophthalmic surgeon at the North Hampshire Hospital in Basingstoke.
Vanessa is the General Counsel at the Alan Turing Institute, the UK’s national data science and artificial intelligence research institute.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
These are some of the most commonly asked questions about genetic testing and counselling.
